Till­man Gern­gross’ Am­ag­ma Ther­a­peu­tics qui­et­ly ships an­ti­bod­ies to an­oth­er biotech

A biotech from an­ti­body leg­end Till­man Gern­gross and stem cell leader Leonard Zon has fold­ed in­to an­oth­er com­pa­ny, merg­ing with an undis­closed biotech.

The duo’s Am­ag­ma Ther­a­peu­tics has tak­en its in­flam­ma­to­ry dis­ease work else­where, ac­cord­ing to an up­date flashed on its web­site in re­cent weeks. Af­ter re­ceiv­ing in­quiries from End­points News last week, Am­ag­ma’s web­site now reads “un­der main­te­nance,” with the words dis­played over an im­age of a sci­en­tist, with no op­tions to fur­ther ex­plore the com­pa­ny’s web­site.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER